Wire · opportunities
FDA Approves Tavapadon for the Treatment of Parkinson Disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
FDA has approved Tavapadon, an oral selective dopamine D1/D5 receptor partial agonist, for the treatment of Parkinson's disease in adults. The approval is supported by phase 3 TEMPO trials showing improvement in motor function and ON time with a safety profile that differs from existing D2/D3 agonists.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 27 Sep 2026 and 29 Sep 2026.
◆ ◆ The Wire takeaway
You gain a new treatment tool with a different receptor target promising fewer typical side effects from dopamine drugs. Parkinson's-focused founders can explore integrations or adjacencies in motor disorder therapies using this novel mechanism.
◆ Coverage
4 sources · first reported 27 Sep 2026 · latest 29 Sep 2026
◆ Related on Wire
◆ Topics